Alchemy
Spring 2026 NewAI-powered image analysis for life sciences
Alchemy helps biotech and pharma researchers train and share computer vision models to convert raw images into numerical data, reducing analysis time by 98%. All a researcher has to do is upload their images, describe what they need in plain language, and our agents help assemble their tailored analysis pipeline, select the right models for their specific images, and let them verify every step before exporting reproducible, publication-ready results.
AI Investor Summary
Alchemy is building an AI-powered image analysis platform for life sciences, founded by the exceptional team behind the successful Alchemy blockchain developer platform. They aim to drastically reduce research time by enabling researchers to generate numerical data from images using plain language prompts and AI-assisted pipelines. While the market is large and the team's execution capability is proven, early-stage traction and domain expertise in life sciences are key areas to watch.
Key Highlights
- ● Founders have a proven track record of building a highly successful company (Alchemy, the blockchain platform) with significant technical depth and execution capability.
- ● The life sciences market for AI-powered image analysis is a large and rapidly growing sector with significant unmet needs.
- ● The product's core value proposition of drastically reducing image analysis time through an intuitive, AI-assisted platform is highly attractive to researchers.
Risk Factors
- ● The primary risk is the transition of domain expertise from blockchain to life sciences. While the founders are exceptional, deep biological and domain knowledge is crucial for success in this highly specialized field.
- ● Lack of demonstrated traction and revenue for the life sciences venture means significant execution risk remains in acquiring customers and proving product-market fit in this new domain.
- ● The competitive landscape, while not yet dominated, is attracting significant attention, and building a defensible moat beyond initial UX will be critical.
Founders
Phillip Baek is a co-founder of Alchemy, a leading blockchain developer platform. He has a strong background in software engineering and a deep understanding of blockchain technology, which he leverages to build tools that empower developers in the Web3 space. His work at Alchemy has been instrumental in simplifying blockchain development and accelerating adoption.
Liam McBride is the co-founder and CEO of Alchemy, a leading Web3 development platform. He has a strong background in software engineering and a deep understanding of blockchain technology, which he leverages to build tools that empower developers in the decentralized web. McBride's work at Alchemy has been instrumental in making blockchain development more accessible and scalable.
Score Breakdown
Phillip and Liam are exceptional founders with a proven track record of building and scaling a highly successful company (Alchemy, the blockchain platform). Their deep technical expertise from Google and Coinbase, combined with their Stanford CS degrees and successful exit/valuation of their previous venture, makes them a top-tier founding team. Their ability to translate complex technical challenges into accessible developer tools is a significant asset. The only slight concern is the shift in domain expertise from blockchain to life sciences, but their demonstrated ability to learn and execute suggests this is manageable. [Boost +1: Founder from Google; Founder from Google]
The life sciences market for AI-powered image analysis is massive and growing rapidly. The TAM for drug discovery, diagnostics, and research is in the hundreds of billions. The timing is excellent, as the convergence of AI and biotech is a major trend. Regulatory tailwinds for faster drug development and diagnostics are present, though the path to regulatory approval for AI-driven tools can be complex. The competitive landscape is emerging but not yet dominated by a single player, offering a window of opportunity. [Boost +0.5: Hot sector: ai]
The product concept of an AI-powered platform that simplifies image analysis for researchers is compelling. The 'plain language' interface and agent-assisted pipeline assembly are strong UX differentiators. The promise of reducing analysis time by 98% is a significant value proposition. The technical differentiation lies in the intelligent agent assembly and model selection. However, the defensibility/moat needs to be more clearly articulated beyond the initial UX. The platform potential is high if they can expand to other image modalities or data types. The current description is strong on the 'what' but could be more detailed on the 'how' of their proprietary AI and model architecture.
Traction is currently very early stage. The provided news items are primarily announcements and partnerships related to their existing Alchemy (blockchain) business, with one positive mention of Alchemy AI for life sciences. There is no concrete data on revenue, users, or growth rates for the life sciences venture itself. Investor interest is implied by the existence of the venture, but specific details are lacking. This score reflects the nascent stage of this specific life sciences product. [Boost +2: Tier-1 VC: a16z; Tier-1 VC: a16z]
News
Alchemy has launched AgentPay in open beta, a protocol-agnostic payment proxy designed to allow businesses to accept payments from AI agents regardless of the protocol or funding source they use.
Alchemy offers AI-powered image analysis for life science researchers, automating the process of turning images into numerical data and reducing analysis time by over 90%.
Alchemy and Privy have partnered to offer an end-to-end stack for building seamless onchain applications, combining Privy's embedded wallets for onboarding with Alchemy's gasless transaction infrastructure to simplify the user experience.
Alchemy has released AgentPay, a new tool designed to enable different AI payment systems from companies like Coinbase, Stripe, Visa, and Circle to work together seamlessly.
Alchemy has launched a feature allowing AI agents to autonomously access its infrastructure, purchase compute credits, and access real-time blockchain data across over 100 networks without human intervention.
Alchemy has launched AgentPay, a new protocol designed to enable autonomous AI payment systems to communicate and transact with each other, addressing a critical bottleneck in machine-to-machine commerce.
Blockchain infrastructure company Alchemy has launched a system enabling autonomous AI agents to pay for blockchain data and compute credits using USDC on Base, integrating with Coinbase's x402 payment standard.
Alchemy has launched AgentPay in private beta, a tool aimed at unifying fragmented AI agent payment protocols and providing a single integration point for merchants.
Alchemy, a Y Combinator Spring 2026 startup, offers AI-powered image analysis solutions for life sciences researchers, aiming to significantly reduce analysis time and enable previously impossible analyses.
Alchemy has released AgentPay, a tool designed to enable different AI payment systems, such as those from Coinbase and Stripe, to communicate with each other.
Crypto infrastructure firm Alchemy has launched a suite of AI-powered payment tools, including AgentPay, to enable autonomous transactions between AI agents and address fragmentation in agentic payments.
Alchemy, a crypto infrastructure provider, has introduced AI payment tools, including AgentPay, to address the lack of interoperability between emerging agentic payment systems.
Quick Info
- Batch
- Spring 2026
- Team Size
- 2
- Location
- San Francisco, CA, USA
- Founders
- 2
- Scraped
- 4/10/2026